| 代码 | 名称 | | 涨跌幅 ^ | 最新价 | 总市值 | | --- | --- | --- | --- | --- | --- | | 06600 | 卧安机器人 | (0) | -10.20% | 145.300 | 327.44亿 | | 02432 | 成5雷 | | -9.96% | 42.320 | 186.19亿 | | 00697 | 首程控股 | | -8.94% | 2.140 | 177.07亿 | | 06682 | 范式智能 | | -9.42% | 40.780 | 211.72亿 | | 02050 | 三花智控 | | -6.68% | 35.780 | 1505.63亿 | | 09880 | 优必选 | | -5.54% | 132.900 | 669.02 Z | | 00020 | 商汤-W | | -5.78% | 2.610 | 1055.07亿 | | 02590 | 极智嘉-W | | -5.02% | 25.720 | 343.95亿 | | 06613 | 蓝思科技 | | -4.58% | 27.100 | 1430.54亿 | | 02252 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

港股市场AI应用股集体飙升，截至收盘，智谱大涨42.72%，股价最高报725港元，总市值突破3200亿港 元；MINIMAX-WP收涨14.52%，市值同样突破3000亿港元；海致科技集团收涨超28%，创上市新高。 | 代码 | 名称 | | 涨跌幅 √ | 最新价 | 总市值 | 年初至今涨跌 | | --- | --- | --- | --- | --- | --- | --- | | 02513 | 智谱 | (0) | 42.72% | 725.000 | 3232.36亿 | 523.92% | | 02706 | 海致科技集团 | | 28.42% | 154.100 | 617.06 Z | 469.48% | | 00100 | MINIMAX-WP | | 14.52% | 970.000 | 3042.26亿 | 487.88% | | 02498 | 速腾聚创 | | 9.24% | 37.580 | 177.45亿 | 2.68% | | 02718 | 明略科技-W | | 5.33% | 256.800 | 373.54亿 | 30.36% | | 02438 | 出门问问 | | ...

Core Viewpoint - The Hong Kong stock market saw a significant rise in robotics concept stocks, driven by the showcase of humanoid robots during the Spring Festival Gala, leading to increased consumer interest and sales in related products [1][2]. Group 1: Market Performance - Robotics stocks such as Yujian surged over 18%, Suton Jichuang increased by over 11%, and Shoucheng Holdings rose by 9% [1]. - Other notable gains included Youbixuan with nearly 9%, Yunjie, Sanhua Intelligent Control, and Jizhi Jia-W each rising over 6%, while MicroPort Scientific and Lijin Technology increased by over 5% [1]. - The total market capitalization for these companies varied, with Youbixuan at 757.12 billion, and Shoucheng Holdings at 189.48 billion [2]. Group 2: Sales Growth - During the Spring Festival period from February 16 to 18, Douyin e-commerce reported a 1680% year-on-year increase in GMV for robot products, with order volume rising by 655% [1]. - The "Spring Festival Gala" effect contributed to the popularity of related products, as several emerging humanoid robot startups showcased their innovations during the event [1].

微创机器人主要提供用于微创手术的手术机器人，其中"图迈"及"鸿鹄"分别为其在腹腔镜及骨科领域的 核心产品。"图迈"是首款经临床验证疗效不逊于达文西手术系统的中国国产腹腔镜手术机器人，而达文 西手术系统乃直觉外科公司(Intuitive Surgical)目前在中国及全球的领先产品。该行相信此项成就确立了 微创机器人作为中国本土龙头企业的地位，使其能够受惠于进口替代趋势。 摩根大通发布研报称，予微创机器人-B(02252)"增持"评级，目标价为41港元。微创机器人核心产品"图 迈"累计订单已突破200台，意味自2026年1月下旬以来新增约20台订单，延续2025年10月至2026年1月的 强劲势头，持续缓解市场对其可持续性的部分担忧。覆盖范围已扩展至逾50个国家及地区(2025年12月 底为40多个)，其中12个市场订购超过五台，主要由新兴市场如印度及巴西领军，而西班牙、澳洲等发 达市场亦取得加速突破。 ...

微创机器人主要提供用于微创手术的手术机器人，其中"图迈"及"鸿鹄"分别为其在腹腔镜及骨科领域的 核心产品。"图迈"是首款经临床验证疗效不逊于达文西手术系统的中国国产腹腔镜手术机器人，而达文 西手术系统乃直觉外科公司(Intuitive Surgical)目前在中国及全球的领先产品。该行相信此项成就确立了 微创机器人作为中国本土龙头企业的地位，使其能够受惠于进口替代趋势。 智通财经APP获悉，摩根大通发布研报称，予微创机器人-Ｂ(02252)"增持"评级，目标价为41港元。微 创机器人核心产品"图迈"累计订单已突破200台，意味自2026年1月下旬以来新增约20台订单，延续2025 年10月至2026年1月的强劲势头，持续缓解市场对其可持续性的部分担忧。覆盖范围已扩展至逾50个国 家及地区(2025年12月底为40多个)，其中12个市场订购超过五台，主要由新兴市场如印度及巴西领军， 而西班牙、澳洲等发达市场亦取得加速突破。 ...

格隆汇2月13日丨微创机器人-B(02252.HK)宣布，公司已收到联交所授出日期为2026年2月13日就 5,989,798股H股(「转换H股」)(即将予转换及上市的非上市股份的总数)上市及买卖的批准。 ...

微创机器人-B(02252)发布公告，公司已收到联交所授出日期为2026年2月13日就598.98万股H股(转换H 股)(即将予转换及上市的非上市股份的总数)上市及买卖的批准。转换及上市将涉及公司两名股东(参与 股东)持有的合计598.98万股非上市股份，占公司于本公告日期已发行股份总数约0.5808%。 ...

Group 1 - The company MicroPort Scientific Corporation-B (02252) has received approval from the Hong Kong Stock Exchange for the listing and trading of 5.9898 million H-shares, which are to be converted and listed [1] - The conversion and listing will involve a total of 5.9898 million unlisted shares held by two shareholders, representing approximately 0.5808% of the total issued shares of the company as of the announcement date [1]

Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 內幕消息公告 聯交所就本公司H股全流通授出上市批准 本公告乃上海微創醫療機器人（集團）股份有限公司（「本公司」）根據香港聯合 交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及證券 及期貨條例（香港法例第571章）第XIVA部（「內幕消息條例」）作出。 茲提述本公司日期為2026年2月4日的公告（「該公告」），內容有關本公司就申請 建議實行H股全流通獲中國證券監督管理委員會發出備案通知書。除另有說明 外，本公告所用詞彙與該公告所界定者具有相同涵義。 聯交所授出上市批准 本公司董事會宣佈，本公司已收到聯交所授出日期為2026年2月13日就5,989,798 股H股（「轉換H ...